Linda L. Neuman - Nov 14, 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Chief Medical Officer
Signature
/s/ James Kastenmayer, by power of attorney
Stock symbol
AGLE
Transactions as of
Nov 14, 2022
Transactions value $
$0
Form type
4
Date filed
1/27/2023, 05:20 PM
Next filing
Feb 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Employee Stock Option (right to buy) Award $0 +25K $0.00 25K Nov 14, 2022 Common Stock 25K $1.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options will vest as to 1/4th of the total shares on November 14, 2023, and then 1/48th of the shares will vest monthly thereafter, such that the option will become fully vested on November 14, 2026, subject to the Reporting Person's provision of service to the issuer on each vesting date.